These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39208744)

  • 1. Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity.
    Stopper D; de Carvalho LP; de Souza ML; Kponomaizoun CE; Winzeler EA; Held J; Hansen FK
    Eur J Med Chem; 2024 Nov; 277():116782. PubMed ID: 39208744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
    Diedrich D; Stenzel K; Hesping E; Antonova-Koch Y; Gebru T; Duffy S; Fisher G; Schöler A; Meister S; Kurz T; Avery VM; Winzeler EA; Held J; Andrews KT; Hansen FK
    Eur J Med Chem; 2018 Oct; 158():801-813. PubMed ID: 30245402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
    Hansen FK; Sumanadasa SD; Stenzel K; Duffy S; Meister S; Marek L; Schmetter R; Kuna K; Hamacher A; Mordmüller B; Kassack MU; Winzeler EA; Avery VM; Andrews KT; Kurz T
    Eur J Med Chem; 2014 Jul; 82():204-13. PubMed ID: 24904967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Activity and Structure-Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity.
    Mackwitz MKW; Hesping E; Antonova-Koch Y; Diedrich D; Woldearegai TG; Skinner-Adams T; Clarke M; Schöler A; Limbach L; Kurz T; Winzeler EA; Held J; Andrews KT; Hansen FK
    ChemMedChem; 2019 May; 14(9):912-926. PubMed ID: 30664827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the in vitro and in vivo efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity.
    Mackwitz MKW; Hesping E; Eribez K; Schöler A; Antonova-Koch Y; Held J; Winzeler EA; Andrews KT; Hansen FK
    Eur J Med Chem; 2021 Feb; 211():113065. PubMed ID: 33360801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Synthesis of Novel Anti-Plasmodial Histone Deacetylase Inhibitors Containing an Alkoxyamide Connecting Unit.
    Alves Avelar LA; Held J; Engel JA; Sureechatchaiyan P; Hansen FK; Hamacher A; Kassack MU; Mordmüller B; Andrews KT; Kurz T
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28317157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, antimalarial properties, and SAR studies of alkoxyurea-based HDAC inhibitors.
    Hansen FK; Skinner-Adams TS; Duffy S; Marek L; Sumanadasa SD; Kuna K; Held J; Avery VM; Andrews KT; Kurz T
    ChemMedChem; 2014 Mar; 9(3):665-70. PubMed ID: 24497437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
    Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
    J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
    Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
    Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Synthesis of Terephthalic Acid-Based Histone Deacetylase Inhibitors with Dual-Stage Anti-Plasmodium Activity.
    Stenzel K; Chua MJ; Duffy S; Antonova-Koch Y; Meister S; Hamacher A; Kassack MU; Winzeler E; Avery VM; Kurz T; Andrews KT; Hansen FK
    ChemMedChem; 2017 Oct; 12(19):1627-1636. PubMed ID: 28812327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors with high in vitro activities against Plasmodium falciparum isolates collected from Gabonese children and adults.
    Koehne E; Kreidenweiss A; Zoleko Manego R; McCall M; Mombo-Ngoma G; Mackwitz MKW; Hansen FK; Held J
    Sci Rep; 2019 Nov; 9(1):17336. PubMed ID: 31758015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing Anticancer Drugs To Tackle Malaria.
    Le Govic Y; Houzé S; Papon N
    ChemMedChem; 2021 Jul; 16(14):2192-2194. PubMed ID: 33931947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.
    Engel JA; Jones AJ; Avery VM; Sumanadasa SD; Ng SS; Fairlie DP; Skinner-Adams T; Andrews KT
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):117-26. PubMed ID: 26199860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules.
    Trenholme K; Marek L; Duffy S; Pradel G; Fisher G; Hansen FK; Skinner-Adams TS; Butterworth A; Ngwa CJ; Moecking J; Goodman CD; McFadden GI; Sumanadasa SD; Fairlie DP; Avery VM; Kurz T; Andrews KT
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3666-78. PubMed ID: 24733477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
    Patel V; Mazitschek R; Coleman B; Nguyen C; Urgaonkar S; Cortese J; Barker RH; Greenberg E; Tang W; Bradner JE; Schreiber SL; Duraisingh MT; Wirth DF; Clardy J
    J Med Chem; 2009 Apr; 52(8):2185-7. PubMed ID: 19317450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.
    Sumanadasa SD; Goodman CD; Lucke AJ; Skinner-Adams T; Sahama I; Haque A; Do TA; McFadden GI; Fairlie DP; Andrews KT
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3849-56. PubMed ID: 22508312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of thiaheterocyclic hHDAC6 inhibitors as potential antiplasmodial agents.
    Vreese R; Kock C; Smith PJ; Chibale K; D'hooghe M
    Future Med Chem; 2017 Mar; 9(4):357-364. PubMed ID: 28263085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QSAR Classification Models for Prediction of Hydroxamate Histone Deacetylase Inhibitor Activity against Malaria Parasites.
    Hesping E; Chua MJ; Pflieger M; Qian Y; Dong L; Bachu P; Liu L; Kurz T; Fisher GM; Skinner-Adams TS; Reid RC; Fairlie DP; Andrews KT; Gorse AJP
    ACS Infect Dis; 2022 Jan; 8(1):106-117. PubMed ID: 34985259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of alkoxyamide-based histone deacetylase inhibitors against Plasmodium falciparum malaria parasites.
    Dawood WA; Fisher GM; Kinnen FJM; Anzenhofer C; Skinner-Adams T; Alves Avelar L; Asfaha Y; Kurz T; Andrews KT
    Exp Parasitol; 2024 Mar; 258():108716. PubMed ID: 38340779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors.
    Diedrich D; Hamacher A; Gertzen CG; Alves Avelar LA; Reiss GJ; Kurz T; Gohlke H; Kassack MU; Hansen FK
    Chem Commun (Camb); 2016 Feb; 52(15):3219-22. PubMed ID: 26810607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.